Kexing Biopharm recently showcased its international strategy and partnership opportunities at the CPHI Frankfurt 2025, held from October 28 to 30, 2025, in Frankfurt, Germany. As one of the most influential pharmaceutical exhibitions worldwide, the event provided a platform for Kexing to present its key product portfolio and international commercialization solutions to potential partners from diverse global markets.
During the exhibition, Kexing Biopharm’s international business team engaged in productive discussions with representatives from various countries. The meetings centered around critical topics such as product registration, market access, and strategies for localized collaboration. Kexing highlighted its comprehensive pharmaceutical capabilities, which span from active pharmaceutical ingredients (APIs) to finished dosage forms, all supported by rigorous quality and regulatory systems compliant with international standards.
Collaboration and Knowledge Sharing
CPHI Frankfurt serves as more than just a venue for product showcases; it acts as an essential bridge for sharing industry information and integrating resources. Kexing’s team actively visited competitor booths, scheduled meetings with clients, and exchanged insights with industry partners. These interactions provided valuable experience that will inform the company’s future overseas expansion strategy and help identify potential clients.
In recent years, Kexing Biopharm has made significant strides with its “Global Selection + Global Coverage” strategy. This approach focuses on identifying and introducing high-quality products in therapeutic areas such as oncology, autoimmune diseases, metabolic disorders, and specialty treatments. By leveraging a platform-based internationalization model, Kexing aims to accelerate the global commercialization of high-quality Chinese medicines.
Commitment to Global Healthcare
Looking ahead, Kexing Biopharm remains dedicated to expanding its footprint in global markets. The company emphasizes open collaboration, professional operations, and a patient-centered approach to deliver accessible, high-quality healthcare solutions to patients across various regions.
With a stock code of 688136.SH, Kexing Biopharm stands as a multinational biopharmaceutical enterprise focused on the research and development, manufacturing, and sales of innovative medicines. These include distinct modalities such as recombinant proteins, antibodies, and cellular and gene therapies. By establishing cutting-edge technology platforms, Kexing aims to develop novel targeted therapies and drug delivery systems that address unmet clinical needs in areas like oncology, autoimmune conditions, and antiviral treatments.
Kexing Biopharm is committed to a platform development model driven by the dual engines of innovation and internationalization. This strategic approach positions the company on a path to becoming a world leader in high-quality biopharmaceuticals, thereby contributing positively to global healthcare and enhancing the lives of patients worldwide.
